ALT
Price
$4.08
Change
-$0.03 (-0.73%)
Updated
Jul 25 closing price
Capitalization
330.92M
11 days until earnings call
XBIO
Price
$3.60
Change
-$0.04 (-1.10%)
Updated
Jul 25 closing price
Capitalization
5.56M
Interact to see
Advertisement

ALT vs XBIO

Header iconALT vs XBIO Comparison
Open Charts ALT vs XBIOBanner chart's image
Altimmune
Price$4.08
Change-$0.03 (-0.73%)
Volume$2.97M
Capitalization330.92M
Xenetic Biosciences
Price$3.60
Change-$0.04 (-1.10%)
Volume$88.58K
Capitalization5.56M
ALT vs XBIO Comparison Chart in %
Loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALT vs. XBIO commentary
Jul 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Hold and XBIO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 28, 2025
Stock price -- (ALT: $4.11 vs. XBIO: $3.60)
Brand notoriety: ALT and XBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 0% vs. XBIO: 95%
Market capitalization -- ALT: $330.92M vs. XBIO: $5.56M
ALT [@Biotechnology] is valued at $330.92M. XBIO’s [@Biotechnology] market capitalization is $5.56M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileXBIO’s FA Score has 1 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • XBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, XBIO is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 5 TA indicator(s) are bullish while XBIO’s TA Score has 3 bullish TA indicator(s).

  • ALT’s TA Score: 5 bullish, 4 bearish.
  • XBIO’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ALT is a better buy in the short-term than XBIO.

Price Growth

ALT (@Biotechnology) experienced а +0.74% price change this week, while XBIO (@Biotechnology) price change was -1.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.60%. For the same industry, the average monthly price growth was +17.32%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

ALT is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+7.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALT($331M) has a higher market cap than XBIO($5.56M). XBIO YTD gains are higher at: -9.687 vs. ALT (-42.996). XBIO has higher annual earnings (EBITDA): -3.88M vs. ALT (-90.75M). ALT has more cash in the bank: 150M vs. XBIO (5.16M). XBIO has less debt than ALT: XBIO (153K) vs ALT (1.59M). XBIO has higher revenues than ALT: XBIO (2.58M) vs ALT (20K).
ALTXBIOALT / XBIO
Capitalization331M5.56M5,956%
EBITDA-90.75M-3.88M2,340%
Gain YTD-42.996-9.687444%
P/E RatioN/AN/A-
Revenue20K2.58M1%
Total Cash150M5.16M2,905%
Total Debt1.59M153K1,037%
FUNDAMENTALS RATINGS
ALT vs XBIO: Fundamental Ratings
ALT
XBIO
OUTLOOK RATING
1..100
697
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
18
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
9559
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XBIO's Valuation (18) in the Biotechnology industry is significantly better than the same rating for ALT (97) in the Miscellaneous Commercial Services industry. This means that XBIO’s stock grew significantly faster than ALT’s over the last 12 months.

XBIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that XBIO’s stock grew similarly to ALT’s over the last 12 months.

XBIO's SMR Rating (97) in the Biotechnology industry is in the same range as ALT (97) in the Miscellaneous Commercial Services industry. This means that XBIO’s stock grew similarly to ALT’s over the last 12 months.

XBIO's Price Growth Rating (59) in the Biotechnology industry is somewhat better than the same rating for ALT (95) in the Miscellaneous Commercial Services industry. This means that XBIO’s stock grew somewhat faster than ALT’s over the last 12 months.

XBIO's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ALT (100) in the Miscellaneous Commercial Services industry. This means that XBIO’s stock grew similarly to ALT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTXBIO
RSI
ODDS (%)
Bullish Trend 3 days ago
66%
Bearish Trend 3 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
86%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
MACD
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 5 days ago
82%
Bullish Trend 4 days ago
85%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 6 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RBGLY15.140.06
+0.40%
Reckitt Benckiser Group Plc.
CDTAF0.03N/A
+0.30%
INFINITII AI INC.
MMSMY7.60N/A
N/A
Mitsu Mining & Smelting Co., Ltd.
SIRZF10.94N/A
N/A
Sir Rty Income Fund
NDBKY13.47-0.22
-1.61%
Nedbank Group, Ltd.

ALT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALT has been loosely correlated with RVPH. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ALT jumps, then RVPH could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALT
1D Price
Change %
ALT100%
N/A
RVPH - ALT
51%
Loosely correlated
+9.63%
INDP - ALT
45%
Loosely correlated
+0.30%
VERA - ALT
39%
Loosely correlated
-0.32%
KROS - ALT
38%
Loosely correlated
+0.56%
OVID - ALT
36%
Loosely correlated
-10.75%
More

XBIO and

Correlation & Price change

A.I.dvisor tells us that XBIO and NKTR have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XBIO and NKTR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XBIO
1D Price
Change %
XBIO100%
-1.00%
NKTR - XBIO
27%
Poorly correlated
+1.71%
ELEV - XBIO
27%
Poorly correlated
N/A
VERA - XBIO
27%
Poorly correlated
-0.32%
ALT - XBIO
26%
Poorly correlated
N/A
CGEN - XBIO
24%
Poorly correlated
-0.65%
More